Karyopharm Therapeutics (KPTI) Capital Expenditures (2013 - 2024)
Karyopharm Therapeutics' (KPTI) quarterly Capital Expenditures came in at -$53000.0 in Q4 2024, down 127.18% on a QoQ basis from $195000.0 in Q1 2024.
Karyopharm Therapeutics (KPTI) Capital Expenditures (2013 - 2024) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 11 years of Capital Expenditures data on file, last reported at -$53000.0 in Q4 2024.
- Quarterly Capital Expenditures changed N/A year-over-year to -$53000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$53000.0 (down 127.18% YoY) and the FY2024 annual result came in at $142000.0, changed N/A from the prior year.
- Capital Expenditures declined to -$53000.0 in Q4 2024, from $195000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $207000.0 in Q4 2021 to a low of -$53000.0 in Q4 2024.
- A 4-year average of $68555.6 and a median of $39000.0 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2020 — Capital Expenditures plunged 79.59% — and 2022, when it soared 680.0%.
- Tracing KPTI's Capital Expenditures over 4 years: stood at $119000.0 in 2020, then soared by 73.95% to $207000.0 in 2021, then slumped by 81.16% to $39000.0 in 2022, then sank by 235.9% to -$53000.0 in 2024.
- The last three Capital Expenditures figures came in at -$53000.0 (Q4 2024), $195000.0 (Q1 2024), and $39000.0 (Q3 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -53,000.00 |
| Dec 31, 2024 | -53,000.00 |
| Mar 31, 2024 | 195,000.00 |
| Mar 31, 2024 | 195,000.00 |
| Sep 30, 2022 | 39,000.00 |
| Sep 30, 2022 | 39,000.00 |
| Mar 31, 2022 | 79,000.00 |
| Mar 31, 2022 | 79,000.00 |
| Dec 31, 2021 | 207,000.00 |
| Dec 31, 2021 | 207,000.00 |
| Sep 30, 2021 | 5,000.00 |
| Sep 30, 2021 | 5,000.00 |
| Dec 31, 2020 | 119,000.00 |
| Dec 31, 2020 | 119,000.00 |
| Jun 30, 2020 | 16,000.00 |
| Jun 30, 2020 | 16,000.00 |
| Mar 31, 2020 | 10,000.00 |
| Mar 31, 2020 | 10,000.00 |
| Dec 31, 2019 | 50,000.00 |
| Dec 31, 2019 | 50,000.00 |